Dana-Farber Cancer Institute (DFCI): Identification of Therapeutic Targets in Ovarian Cancer
The goal of this project is to systematically identify and validate therapeutic targets in ovarian cancer by integrating information from cancer genomics and cancer dependencies projects.
A. shRNA Screening in Ovarian Cancer with Candidate BRD4 Analysis
An shRNA-based negative selection screen was designed to search for genes necessary for survival/proliferation of an ovarian cancer cell line growing as tumor masses in immunocompromised mice. One candidate, BRD4, was confirmed using both genetic and pharmacologic approaches.
To detect active genes in the in vivo expansion of high-grade serous ovarian cancer (HGSOC), an in vivo shRNA screen was designed for use in human xenografts of a HGSOC cell line (OVCAR8). The screen was used to test the effects on viability of depleting a library encoding ∼8,000 shRNAs directed at all human protein kinases plus ∼300 putative oncoproteins.
Read the detailed Experimental Approaches
Access the Raw/Analyzed Data (DCC)
Access the Dashboard Submission(s)
For questions, please contact Joshua Dempster.